To bet­ter com­bat Chi­na and Aus­trali­a's dom­i­nance in ex­pe­dit­ing ear­ly-phase tri­als, the FDA and stake­hold­ers are iron­ing out the de­tails of a pi­lot pro­gram to...

Jazz Phar­ma­ceu­ti­cals’ bis­pe­cif­ic an­ti­body Zi­ihera won a la­bel ex­pan­sion to treat cer­tain pa­tients with gas­tric can­cer.

It’s the first time Zi­ihera will be mar­ket­ed to...

Bausch + Lomb’s dual-ac­tion drop for dry eye failed a Phase 2 study, the com­pa­ny ex­clu­sive­ly told End­points News on Mon­day. But CEO Brent Saun­ders claims...

Af­ter a “com­pre­hen­sive eval­u­a­tion,” Bris­tol My­ers Squibb has pulled out of its part­ner­ship with Cel­lares and the cell ther­a­py man­u­fac­tur­er will re­struc­ture as a re­sult...

J&J’s Imaavy wins la­bel ex­pan­sion: The mon­o­clon­al an­ti­body is now the first treat­ment ap­provedspecif­i­cal­ly for warm au­toim­mune he­molyt­ic ane­mia, a rare au­toan­ti­body dis­ease that...

As AI aims to ac­cel­er­ate drug dis­cov­ery,a grow­ing num­ber of health tech com­pa­nies are bet­ting that the abil­i­ty to pro­vide health da­ta for train­ing...